Future of Novartis | Quantumrun

Future of Novartis

Novartis International AG is a Swiss global pharmaceutical company based in Basel, Switzerland. It is one of the biggest pharmaceutical companies by both sales cap and market.

Novartis produces the drugs carbamazepine (Tegretol), imatinib mesylate (Gleevec/Glivec), clozapine (Clozaril), diclofenac (Voltaren), and valsartan (Diovan). Additional agents include letrozole (Femara), terbinafine (Lamisil), ciclosporin (Neoral/Sandimmun), methylphenidate (Ritalin), and others.

Home Country: 
Switzerland
Industry: 
Pharmaceuticals
Industry vulnerability to disruption: 

<p>Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:</p>

<p>*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.<br />
*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.<br />
*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.<br />
*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.<br />
*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.<br />
*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.<br />
*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.</p>

Total patents held: 
1
Ranking List: 
182
Ranking List: 
2017 Quantumrun Global 1000
Ranking List: 
2017 Quantumrun US 500
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Prod/Serv name revenue: 
Prod/Serv name: 
Innovative medicines
Prod/Serv revenue: 
32562000000
Prod/Serv name: 
Sandoz
Prod/Serv revenue: 
10144000000
Prod/Serv name: 
Alcon
Prod/Serv revenue: 
5812000000
Founded: 
1996
Global brand rank: 
462
Company Name: 
Novartis
Sector: 
Revenue: 
48518000000
3y average revenue: 
50037333333
Operating expenses: 
25575000000
3y average expenses: 
26073666667
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
118393
Number of domestic locations: 
6
Funds in reserve: 
7777000000
Investment into R&D: 
2645000000
create term: 
#182 | 2017 Quantumrun Global 1000

Novartis International AG is a Swiss global pharmaceutical company based in Basel, Switzerland. It is one of the biggest pharmaceutical companies by both sales cap and market.

Novartis produces the drugs carbamazepine (Tegretol), imatinib mesylate (Gleevec/Glivec), clozapine (Clozaril), diclofenac (Voltaren), and valsartan (Diovan). Additional agents include letrozole (Femara), terbinafine (Lamisil), ciclosporin (Neoral/Sandimmun), methylphenidate (Ritalin), and others.

Home country:
Switzerland
Sector:
Health Care
Industry:
Pharmaceuticals
Website:
Founded:
1996
Global employee count:
118,393

Financial Health

Revenue
$48,518,000,000 USD
3y average revenue
$50,037,333,333 USD
Operating expenses
$25,575,000,000 USD
3y average expenses
$26,073,666,667 USD
Funds in reserve
$7,777,000,000 USD

Asset Performance

#1 Product/Service/Dept. name
Innovative medicines
#1 Product/Service revenue
$32,562,000,000 USD
#2 Product/Service/Dept. name
Sandoz
#2 Product/Service revenue
$10,144,000,000 USD
#3 Product/Service/Dept. name
Alcon
#3 Product/Service revenue
$5,812,000,000 USD

Innovation assets and Pipeline

Global brand rank
462
Investment into R&D
$2,645,000,000 USD
Total patents held
1
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.

*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.

*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.

*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.

*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.

*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.

*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.